Neurocrine Biosciences (NBIX) Stock Forecast, Price Target & Predictions
NBIX Stock Forecast
Neurocrine Biosciences stock forecast is as follows: an average price target of $147.70 (represents a 22.54% upside from NBIX’s last price of $120.53) and a rating consensus of 'Buy', based on 19 wall street analysts offering a 1-year stock forecast.
NBIX Price Target
The average price target for Neurocrine Biosciences (NBIX) is $147.70 based on 1-year price targets from 19 Wall Street analysts in the past 3 months, with a price target range of $193.00 to $100.00. This represents a potential 22.54% upside from NBIX's last price of $120.53.
NBIX Analyst Ratings
According to 19 Wall Street analysts, Neurocrine Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for NBIX stock is 0 'Strong Buy' (0.00%), 14 'Buy' (73.68%), 4 'Hold' (21.05%), 1 'Sell' (5.26%), and 0 'Strong Sell' (0.00%).
Neurocrine Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 22, 2024 | Jay Olson | Oppenheimer | $192.00 | $116.57 | 64.71% | 59.30% |
| Oct 10, 2024 | Danielle Brill | Raymond James | $155.00 | $111.62 | 38.86% | 28.60% |
| Sep 13, 2024 | Evan David Seigerman | BMO Capital | $128.00 | $122.29 | 4.67% | 6.20% |
| Sep 09, 2024 | Carter Gould | Barclays | $160.00 | $120.17 | 33.14% | 32.75% |
| Aug 29, 2024 | Brian Abrahams | RBC Capital | $136.00 | $123.76 | 9.89% | 12.83% |
| Aug 29, 2024 | David Amsellem | Piper Sandler | $159.00 | $128.43 | 23.80% | 31.92% |
| Jul 12, 2024 | Jeffrey Hung | Morgan Stanley | $170.00 | $146.50 | 16.04% | 41.04% |
| Jun 06, 2024 | Brian Abrahams | RBC Capital | $141.00 | $133.69 | 5.47% | 16.98% |
| May 28, 2024 | Ashwani Verma | UBS | $193.00 | $139.40 | 38.45% | 60.13% |
| May 13, 2024 | Cory Kasimov | Evercore ISI | $175.00 | $136.15 | 28.53% | 45.19% |
The latest Neurocrine Biosciences stock forecast, released on Oct 22, 2024 by Jay Olson from Oppenheimer, set a price target of $192.00, which represents a 64.71% increase from the stock price at the time of the forecast ($116.57), and a 59.30% increase from NBIX last price ($120.53).
Neurocrine Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 6 | 14 |
| Avg Price Target | $173.50 | $155.00 | $164.50 |
| Last Closing Price | $120.53 | $120.53 | $120.53 |
| Upside/Downside | 43.95% | 28.60% | 36.48% |
In the current month, the average price target of Neurocrine Biosciences stock is $173.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 43.95% increase as opposed to Neurocrine Biosciences's last price of $120.53. This month's average price target is up 11.94% compared to last quarter, and up 5.47% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | RBC Capital | Market Perform | Market Perform | Hold |
| Oct 29, 2024 | Raymond James | Underperform | Underperform | Hold |
| Oct 22, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 04, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Oct 04, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Sep 13, 2024 | William Blair | Outperform | Outperform | Hold |
| Sep 13, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| Sep 09, 2024 | RBC Capital | Market Perform | Market Perform | Hold |
| Sep 09, 2024 | Piper Sandler | Underperform | Underperform | Hold |
Neurocrine Biosciences's last stock rating was published by RBC Capital on Oct 29, 2024. The company gave NBIX a "Market Perform" rating, the same as its previous rate.
Neurocrine Biosciences Financial Forecast
Neurocrine Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $498.80M | $452.70M | $420.40M | $412.00M | $387.90M | $378.20M | $310.60M | $312.00M | $296.00M | $288.90M | $236.60M | $247.90M | $258.50M | $302.40M | $237.10M | $244.01M | $222.09M |
| Avg Forecast | $899.46M | $868.51M | $836.75M | $798.88M | $744.24M | $707.29M | $673.10M | $624.59M | $628.23M | $600.64M | $545.98M | $512.40M | $518.52M | $479.09M | $447.34M | $410.66M | $408.87M | $377.00M | $342.33M | $304.07M | $317.49M | $297.83M | $273.19M | $250.67M | $260.45M | $282.70M | $261.31M | $226.53M | $231.54M | $211.97M |
| High Forecast | $929.45M | $897.47M | $864.65M | $825.51M | $769.05M | $730.87M | $695.55M | $643.04M | $642.57M | $601.79M | $545.98M | $512.40M | $522.66M | $506.87M | $462.25M | $424.35M | $422.50M | $377.00M | $342.33M | $304.07M | $317.49M | $297.83M | $273.19M | $250.67M | $260.45M | $282.70M | $261.31M | $226.53M | $231.54M | $211.97M |
| Low Forecast | $866.50M | $836.68M | $806.08M | $769.60M | $716.96M | $681.36M | $648.43M | $610.01M | $614.57M | $599.48M | $545.98M | $512.40M | $513.94M | $279.75M | $430.94M | $395.61M | $393.88M | $377.00M | $342.33M | $304.07M | $317.49M | $297.83M | $273.19M | $250.67M | $260.45M | $282.70M | $261.31M | $226.53M | $231.54M | $211.97M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 17 | 15 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.01% | 1.02% | 1.01% | 1.03% | 1.10% | 1.02% | 0.98% | 0.99% | 1.06% | 0.94% | 0.95% | 0.91% | 1.16% | 1.05% | 1.05% | 1.05% |
Neurocrine Biosciences's average Quarter revenue forecast for Dec 23 based on 12 analysts is $518.52M, with a low forecast of $513.94M, and a high forecast of $522.66M. NBIX's average Quarter revenue forecast represents a 3.95% increase compared to the company's last Quarter revenue of $498.80M (Sep 23).
Neurocrine Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 17 | 15 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $141.20M | $73.60M | $29.70M | $103.40M | $91.80M | $58.60M | $6.40M | $-4.20M | $39.90M | $66.30M | $36.10M | $51.70M | $-46.40M | $93.60M | $49.20M | $48.86M | $68.45M |
| Avg Forecast | $210.79M | $203.53M | $196.09M | $187.21M | $174.41M | $165.75M | $157.74M | $146.37M | $147.23M | $140.76M | $127.95M | $47.57M | $121.51M | $112.27M | $104.83M | $43.24M | $-8.86M | $88.35M | $80.22M | $39.31M | $74.40M | $69.80M | $64.02M | $48.84M | $61.04M | $66.25M | $61.24M | $62.87M | $54.26M | $49.68M |
| High Forecast | $217.81M | $210.32M | $202.63M | $193.46M | $180.23M | $171.28M | $163.00M | $150.70M | $150.59M | $141.03M | $127.95M | $57.08M | $122.48M | $118.78M | $108.33M | $51.89M | $-7.09M | $88.35M | $80.22M | $47.17M | $74.40M | $69.80M | $64.02M | $58.61M | $61.04M | $66.25M | $61.24M | $75.44M | $54.26M | $49.68M |
| Low Forecast | $203.06M | $196.07M | $188.90M | $180.35M | $168.02M | $159.68M | $151.96M | $142.95M | $144.02M | $140.49M | $127.95M | $38.05M | $120.44M | $65.56M | $100.99M | $34.59M | $-10.63M | $88.35M | $80.22M | $31.45M | $74.40M | $69.80M | $64.02M | $39.07M | $61.04M | $66.25M | $61.24M | $50.29M | $54.26M | $49.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.26% | 0.70% | 0.69% | -11.67% | 1.04% | 0.73% | 0.16% | -0.06% | 0.57% | 1.04% | 0.74% | 0.85% | -0.70% | 1.53% | 0.78% | 0.90% | 1.38% |
12 analysts predict NBIX's average Quarter EBITDA for Dec 23 to be $121.51M, with a high of $122.48M and a low of $120.44M. This is -13.94% lower than Neurocrine Biosciences's previous annual EBITDA (Sep 23) of $141.20M.
Neurocrine Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 17 | 15 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $83.10M | $95.50M | $-76.60M | $89.00M | $68.50M | $-16.90M | $13.90M | $-7.30M | $22.50M | $42.30M | $32.10M | $347.90M | $-57.60M | $79.60M | $37.40M | $34.00M | $53.79M |
| Avg Forecast | $285.47M | $264.78M | $249.49M | $217.75M | $200.14M | $176.68M | $159.79M | $143.10M | $162.07M | $158.19M | $117.69M | $24.22M | $126.41M | $108.41M | $84.96M | $22.02M | $-15.40M | $84.11M | $63.26M | $20.02M | $70.39M | $57.85M | $52.15M | $43.43M | $62.49M | $-2.02M | $68.70M | $47.79M | $80.68M | $68.98M |
| High Forecast | $297.84M | $276.25M | $260.30M | $227.19M | $208.81M | $184.34M | $166.71M | $174.54M | $339.36M | $159.99M | $117.70M | $29.06M | $161.09M | $149.34M | $88.64M | $26.42M | $-12.32M | $84.11M | $63.26M | $24.02M | $70.39M | $57.85M | $52.15M | $52.12M | $62.49M | $-2.02M | $68.70M | $57.35M | $80.68M | $68.98M |
| Low Forecast | $271.87M | $252.16M | $237.60M | $207.37M | $190.60M | $168.27M | $152.17M | $122.50M | $125.36M | $156.40M | $117.67M | $19.38M | $46.98M | $38.72M | $80.91M | $17.61M | $-18.48M | $84.11M | $63.26M | $16.01M | $70.39M | $57.85M | $52.15M | $34.74M | $62.49M | $-2.02M | $68.70M | $38.23M | $80.68M | $68.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 1.12% | -3.48% | -5.78% | 0.81% | -0.27% | 0.69% | -0.10% | 0.39% | 0.81% | 0.74% | 5.57% | 28.56% | 1.16% | 0.78% | 0.42% | 0.78% |
Neurocrine Biosciences's average Quarter net income forecast for Dec 23 is $126.41M, with a range of $46.98M to $161.09M. NBIX's average Quarter net income forecast represents a 52.12% increase compared to the company's last Quarter net income of $83.10M (Sep 23).
Neurocrine Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 17 | 15 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $204.20M | $221.80M | $242.70M | $182.90M | $186.30M | $182.80M | $200.70M | $156.50M | $154.60M | $143.20M | $129.00M | $106.50M | $112.50M | $96.50M | $117.80M | $101.21M | $84.49M |
| Avg Forecast | $423.50M | $408.92M | $393.97M | $376.14M | $350.41M | $333.01M | $316.92M | $294.08M | $295.79M | $282.80M | $257.06M | $349.70M | $244.14M | $225.57M | $210.62M | $317.91M | $330.19M | $177.50M | $161.18M | $289.01M | $149.49M | $140.23M | $128.62M | $174.53M | $122.63M | $133.10M | $123.04M | $150.52M | $109.02M | $99.80M |
| High Forecast | $437.61M | $422.56M | $407.10M | $388.68M | $362.09M | $344.12M | $327.48M | $302.76M | $302.54M | $283.34M | $257.06M | $419.64M | $246.08M | $238.65M | $217.64M | $381.49M | $396.23M | $177.50M | $161.18M | $346.81M | $149.49M | $140.23M | $128.62M | $209.44M | $122.63M | $133.10M | $123.04M | $180.63M | $109.02M | $99.80M |
| Low Forecast | $407.97M | $393.93M | $379.53M | $362.35M | $337.57M | $320.81M | $305.30M | $287.21M | $289.36M | $282.25M | $257.06M | $279.76M | $241.98M | $131.72M | $202.90M | $254.33M | $264.15M | $177.50M | $161.18M | $231.21M | $149.49M | $140.23M | $128.62M | $139.62M | $122.63M | $133.10M | $123.04M | $120.42M | $109.02M | $99.80M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.05% | 0.76% | 0.55% | 1.05% | 1.13% | 0.69% | 1.05% | 1.10% | 1.11% | 0.74% | 0.87% | 0.85% | 0.78% | 0.78% | 0.93% | 0.85% |
Neurocrine Biosciences's average Quarter SG&A projection for Dec 23 is $244.14M, based on 12 Wall Street analysts, with a range of $241.98M to $246.08M. The forecast indicates a 19.56% rise compared to NBIX last annual SG&A of $204.20M (Sep 23).
Neurocrine Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 17 | 15 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | $-0.18 | $0.15 | $-0.08 | $0.24 | $0.45 | $0.34 | $3.72 | $-0.62 | $0.86 | $0.40 | $0.37 | $0.59 |
| Avg Forecast | $2.74 | $2.54 | $2.39 | $2.09 | $1.92 | $1.69 | $1.53 | $1.37 | $1.55 | $1.52 | $1.13 | $1.10 | $1.21 | $1.04 | $0.81 | $0.62 | $1.12 | $0.81 | $0.61 | $0.35 | $0.68 | $0.56 | $0.50 | $0.53 | $0.60 | $-0.02 | $0.66 | $0.52 | $0.78 | $0.66 |
| High Forecast | $2.86 | $2.65 | $2.50 | $2.18 | $2.00 | $1.77 | $1.60 | $1.67 | $3.25 | $1.53 | $1.13 | $1.10 | $1.54 | $1.43 | $0.85 | $0.64 | $1.17 | $0.81 | $0.61 | $0.35 | $0.68 | $0.56 | $0.50 | $0.53 | $0.60 | $-0.02 | $0.66 | $0.52 | $0.78 | $0.66 |
| Low Forecast | $2.61 | $2.42 | $2.28 | $1.99 | $1.83 | $1.61 | $1.46 | $1.17 | $1.20 | $1.50 | $1.13 | $1.10 | $0.45 | $0.37 | $0.78 | $0.59 | $1.07 | $0.81 | $0.61 | $0.35 | $0.68 | $0.56 | $0.50 | $0.53 | $0.60 | $-0.02 | $0.66 | $0.52 | $0.78 | $0.66 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | 1.20% | -1.28% | 0.82% | 0.89% | -0.30% | 0.43% | -0.11% | 0.43% | 0.90% | 0.64% | 6.19% | 31.94% | 1.30% | 0.77% | 0.48% | 0.89% |
According to 12 Wall Street analysts, Neurocrine Biosciences's projected average Quarter EPS for Dec 23 is $1.21, with a low estimate of $0.45 and a high estimate of $1.54. This represents a 42.59% increase compared to NBIX previous annual EPS of $0.85 (Sep 23).
Neurocrine Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals | $4.19 | $11.67 | 178.52% | Buy |
| PCRX | Pacira BioSciences | $16.45 | $40.00 | 143.16% | Hold |
| DVAX | Dynavax | $11.79 | $24.50 | 107.80% | Buy |
| EVO | Evotec SE | $4.40 | $8.00 | 81.82% | Buy |
| ANIP | ANI Pharmaceuticals | $56.01 | $79.00 | 41.05% | Buy |
| AMPH | Amphastar Pharmaceuticals | $50.59 | $66.00 | 30.46% | Buy |
| ALKS | Alkermes | $26.59 | $34.38 | 29.30% | Hold |
| COLL | Collegium Pharmaceutical | $32.72 | $41.50 | 26.83% | Buy |
| NBIX | Neurocrine Biosciences | $120.53 | $147.70 | 22.54% | Buy |
| AVDL | Avadel Pharmaceuticals | $14.86 | $17.80 | 19.78% | Buy |
| PBH | Prestige Consumer Healthcare | $73.79 | $82.00 | 11.13% | Buy |
| ITCI | Intra-Cellular Therapies | $86.17 | $94.50 | 9.67% | Buy |
| SUPN | Supernus Pharmaceuticals | $34.70 | $38.00 | 9.51% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
NBIX Forecast FAQ
Is Neurocrine Biosciences a good buy?
Yes, according to 19 Wall Street analysts, Neurocrine Biosciences (NBIX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 73.68% of NBIX's total ratings.
What is NBIX's price target?
Neurocrine Biosciences (NBIX) average price target is $147.7 with a range of $100 to $193, implying a 22.54% from its last price of $120.53. The data is based on 19 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Neurocrine Biosciences stock go up soon?
According to Wall Street analysts' prediction for NBIX stock, the company can go up by 22.54% (from the last price of $120.53 to the average price target of $147.7), up by 60.13% based on the highest stock price target, and down by -17.03% based on the lowest stock price target.
Can Neurocrine Biosciences stock reach $200?
NBIX's average twelve months analyst stock price target of $147.7 does not support the claim that Neurocrine Biosciences can reach $200 in the near future.
What is Neurocrine Biosciences's current price target trend?
2 Wall Street analysts forecast a $173.5 price target for Neurocrine Biosciences (NBIX) this month, up 43.95% from its last price of $120.53. Compared to the last 3 and 12 months, the average price target increased by 28.60% and increased by 36.48%, respectively.
What are Neurocrine Biosciences's analysts' financial forecasts?
Neurocrine Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.75B (high $2.84B, low $2.66B), average EBITDA is $644.27M (high $665.2M, low $622.61M), average net income is $679.71M (high $734.41M, low $633.55M), average SG&A $1.29B (high $1.34B, low $1.25B), and average EPS is $6.52 (high $7.04, low $6.07). NBIX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.4B (high $3.52B, low $3.28B), average EBITDA is $797.63M (high $824.22M, low $768.39M), average net income is $1.02B (high $1.06B, low $968.99M), average SG&A $1.6B (high $1.66B, low $1.54B), and average EPS is $9.76 (high $10.18, low $9.29).
Did the NBIX's actual financial results beat the analysts' financial forecasts?
Based on Neurocrine Biosciences's last annual report (Dec 2023), the company's revenue was $1.89B, beating the average analysts forecast of $1.86B by 1.70%. Apple's EBITDA was $250.9M, missing the average prediction of $381.86M by -34.30%. The company's net income was $249.7M, missing the average estimation of $341.8M by -26.95%. Apple's SG&A was $887.6M, missing the average forecast of $998.23M by -11.08%. Lastly, the company's EPS was $2.56, missing the average prediction of $3.68 by -30.49%. In terms of the last quarterly report (Sep 2023), Neurocrine Biosciences's revenue was $498.8M, beating the average analysts' forecast of $479.09M by 4.12%. The company's EBITDA was $141.2M, beating the average prediction of $112.27M by 25.77%. Neurocrine Biosciences's net income was $83.1M, missing the average estimation of $108.41M by -23.35%. The company's SG&A was $204.2M, missing the average forecast of $225.57M by -9.47%. Lastly, the company's EPS was $0.85, missing the average prediction of $1.04 by -18.22%